Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A Vaccine

A Phase Ⅲ Clinical Trial to Evaluate the Immunogenicity and Safety of an Inactivated Hepatitis A Vaccine (Human Diploid Cell) in Healthy Adults and Children Aged ≥1 Year

This is a Phase Ⅲ, open-label, single arm design combined with randomized, double-blind, active-controlled design trial to assess the immunogenicity and safety of different specifications of Healive® (the 0.5 mL pediatric dosage and the 1 mL adult dosage).

A total of 680 healthy participants aged 1 year and above will be enrolled, including 200 participants aged 16 years and older (adult dose group), and 480 participants aged 1 to less than 16 years (pediatric dose group).

For the adult dose group: open-label, single-arm design, 200 participants aged 16 years and above will be enrolled to receive Healive® (1.0 mL).

For the pediatric dose group: double-blinded, randomized, positive-controlled design, 480 participants aged 1 to less than 16 years will be enrolled, and randomized in a 2:1 ratio to receive either Healive® (0.5 mL) or Avaxim® (0.5 mL). All participants will receive two doses of either Healive® or Avaxim® at 0 and 6 months.

Study Overview

• Status: Recruiting
• Conditions: Hepatitis A Vaccine
• Intervention / Treatment: Biological: Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL); Biological: Inactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 mL); Biological: Hepatitis A vaccine (inactivated, adsorbed)

• Study Type: Interventional
• Enrollment (Estimated): 680
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Van Anh Thi Pham; Phone Number: 84 915595690; Email: phamthivananh.hmu@gmail.com

Study Locations

• Vietnam
  • Hanoi, Vietnam
    • Recruiting
    • Hanoi Medical University
    • Contact: Van Anh Thi Pham; Phone Number: 84 915595690; Email: phamthivananh.hmu@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Healthy participants aged 1 year and older;
2. Participants (and/or their legal guardians) are able to understand and sign the informed consent voluntarily;
3. Participants of reproductive potential and their sexual partners should voluntarily use effective contraception from signing the ICF to 30 days after the second vaccination and avoid donating sperm or eggs.
4. Participants should provide verifiable identification, to be contacted, and to contact the investigator during the study period.
5. Participants should agree to comply with the lifestyle precautions outlined in the protocol.

Exclusion Criteria:

1. Prior vaccination with any hepatitis A vaccine or combined vaccines containing HAV components;
2. Prior history of HAV infection;
3. Female participants of reproductive potential who are pregnant (including a positive urine pregnancy test) or have a pregnancy plan within 30 days after the second vaccination, or who are currently lactating;
4. Known allergy to vaccines or vaccines ingredients;
5. Autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, and HIV infection);
6. Coagulation disorders (e.g. factor deficiency, platelet disorders), or history of bleeding, hematoma, or bruising following intramuscular injections or venipuncture;
7. Poorly controlled chronic illnesses or history of severe diseases that, including but not limited to cardiovascular diseases, hematological disorders, liver and kidney diseases, digestive system disorders, respiratory diseases, malignancies, and a history of major organ transplantation;
8. Current or history of severe neurological diseases [epilepsy, convulsions or seizures (excluding history of febrile seizures)] or psychiatric disorders, or presence of a family history of psychiatric disorders;
9. Receipt of ≥14 days of immunosuppressive or other immunomodulatory therapy (prednisone ≥20mg/day, or prednisone ≥2mg/kg/day, or its equivalent), cytotoxic therapy within 180 days prior to screening, or plans for such treatment during the trial;
10. Receipt of blood products or immunoglobulins within 180 days prior to screening, or plans to receive these treatments in the trial;
11. Receipt of other investigational drugs/vaccines within 30 days prior to screening, or plans to receive such drugs or vaccines during the study period;
12. Receipt of attenuated live vaccines or nucleic acid vaccines within 14 days prior to screening, or subunit or inactivated vaccines within 7 days prior to screening;
13. Fever on vaccination day, with axillary temperature >37.2°C pre-vaccination, or vital signs outside normal range, or failure to pass physical examination;
14. Presence of skin injuries, inflammation, ulcers, rashes, scars, or other conditions at the intended injection site that may interfere with drug administration or observation of local reactions;
15. Acute onset of various acute diseases or chronic diseases within the past 7 days, or known or suspected active infections;
16. Any other factors considered by the investigator to make the participant unsuitable for participation in the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Adult dose, treatment group (≥16 years)	Biological: Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL); Inactivated Hepatitis A Vaccine (Human Diploid Cell) manufactured by Sinovac, adult dose (≥ 16 years); Other Names: Healive® (1 mL)
Experimental: Pediatric dose, treatment group (6~ <16 years)	Biological: Inactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 mL); Inactivated Hepatitis A Vaccine (Human Diploid Cell) manufactured by Sinovac, pediatric dose (1~<16 years); Other Names: Healive® (0.5 mL)
Active Comparator: Pediatric dose, control group (6~ <16 years)	Biological: Hepatitis A vaccine (inactivated, adsorbed); Hepatitis A vaccine (inactivated, adsorbed) manufactured by Sanofi
Experimental: Pediatric dose, treatment group (1~ <6 years)	Biological: Inactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 mL); Inactivated Hepatitis A Vaccine (Human Diploid Cell) manufactured by Sinovac, pediatric dose (1~<16 years); Other Names: Healive® (0.5 mL)
Active Comparator: Pediatric dose, conrol group (1~ <6 years)	Biological: Hepatitis A vaccine (inactivated, adsorbed); Hepatitis A vaccine (inactivated, adsorbed) manufactured by Sanofi

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Seroconversion rate of anti-HAV antibodies	The seroconversion rate of anti-hepatitis A virus (HAV) antibodies 30 days after the second vaccination	30 days after the second vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Seropositive rate of anti-HAV antibodies	The seropositive rate of anti-HAV antibodies 30 days after the second vaccination	30 days after the second vaccination
Geometric mean concentration (GMC) of anti-HAV antibodies	The geometric mean concentration (GMC) of anti-HAV antibodies 30 days after the second vaccination	30 days after the second vaccination
Geometric mean fold rise (GMFR) of anti-HAV antibodies	The geometric mean fold rise (GMFR) of anti-HAV antibodies 30 days after the second vaccination	30 days after the second vaccination
Incidence of adverse events (AE)/adverse reactions (AR)	Incidence of adverse events (AE)/adverse reactions (AR) within 30 days after each vaccination	30 days after each vaccination
Incidence of adverse events (AE)/adverse reactions (AR)	Incidence of AE/AR within 7 days after each vaccination	7 days after each vaccination
Incidence of serious adverse events (SAE)	Incidence of serious adverse events (SAE) from first vaccination to 30 days after second vaccination	From first vaccination to 30 days after second vaccination

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
The seroconversion rate of HAV antibodies	The seroconversion rate of HAV antibodies 30 days after the second vaccination in susceptible population	30 days after the second vaccination
The seropositive rate of anti-HAV antibodies	The seropositive rate of anti-HAV antibodies 30 days after the first vaccination	30 days after the first vaccination
The seroconversion rate of anti-HAV antibodies	The seroconversion rate of anti-HAV antibodies 30 days after the first vaccination	30 days after the first vaccination
The GMC of anti-HAV antibodies	The GMC of anti-HAV antibodies 30 days after the first vaccination	30 days after the first vaccination
The GMFR of anti-HAV antibodies	The GMFR of anti-HAV antibodies 30 days after the first vaccination	30 days after the first vaccination

Collaborators and Investigators

• Sponsor: Sinovac Biotech Co., Ltd
• Collaborators: DUC MINH MEDICAL JSC.

Study record dates

Study Major Dates

• Study Start (Actual): August 20, 2026
• Primary Completion (Estimated): September 15, 2027
• Study Completion (Estimated): September 15, 2027

Study Registration Dates

• First Submitted: August 25, 2026
• First Submitted That Met QC Criteria: August 25, 2026
• First Posted (Actual): August 28, 2026

Study Record Updates

• Last Update Posted (Actual): August 28, 2026
• Last Update Submitted That Met QC Criteria: August 25, 2026
• Last Verified: August 1, 2026

More Information

Terms related to this study

• Keywords: Safety; Immunogenicity; Hepatitis A Vaccine
• Additional Relevant MeSH Terms: Digestive System Diseases; Liver Diseases; Hepatitis; Biological Products; Complex Mixtures; Vaccines; Viral Vaccines; Viral Hepatitis Vaccines; Hepatitis A Vaccines
• Other Study ID Numbers: PRO-HAV-4018

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No